- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04416126
Safety, Tolerability and Pharmacokinetics of ARCT-810 in Healthy Adult Subjects
A Phase 1 Randomized, Double Blinded, Placebo Controlled, Ascending Dose Study to Assess the Safety, Tolerability, and Pharmacokinetics of Single Doses of ARCT-810 in Healthy Adult Subjects
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This is a single ascending dose study of ARCT-810 in which approximately 30 subjects are planned to be enrolled. The length of each study participant is approximately 8 weeks from screening to last study visit.
Study participants will be allocated to one of the five different study groups (also called cohorts), to test different doses of ARCT-810. There will be 6 participants in each group. Within each cohort, subjects will be randomized 2:1 to receive ARCT-810 or placebo as an IV infusion.
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
-
Auckland, New Zealand
- Auckland Clinical Studies (ACS) Ltd.
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Healthy males or females aged 18 to 65 at the time of informed consent.
- Body weight ≤ 100Kg and body mass index <35 kg/m2
- Willing to refrain from strenuous exercise/activity (for example heavy lifting, weight training, intense aerobics classes etc.) and alcohol for at least 72 hours prior to study visits and willing to refrain from taking protein supplements for the duration of the study.
- Willing and able to comply with protocol-defined procedures and complete all study visits
- Males must be surgically sterile or, if engaged in sexual relations with a female of child-bearing potential, the subject must be using an acceptable contraceptive method from the time of signing the informed consent form until at least 30 days after the last dose of Study Drug. Females: must be non-pregnant and non-lactating and either: i. surgically sterile or ii. post-menopausal
Exclusion Criteria:
- Clinically significant abnormalities in medical history
Screening laboratory results as follows:
- ALT, AST, GGT, total bilirubin or alkaline phosphatase, > ULN.
- Random blood glucose and/or HbA1c > ULN
- Hemoglobin < LLN
- Platelet count < 100x109/L
- Estimated glomerular filtration rate (eGFR) < 60 mL/min/1.73m2 calculated by Modification to Diet in Renal Disease [MDRD] study equation.
- Urine protein:creatinine ratio (UPCR) > 50 mg/mmol
- Active infection requiring systemic antiviral or antimicrobial therapy that will not be completed within 7 days prior to Study Day 1
- Known history of or positive test for human immunodeficiency virus (HIV), hepatitis C or chronic hepatitis B
- Uncontrolled hypertension (BP > 160/100 mm Hg)
- Treatment with another investigational drug, biological agent, or device within one month of screening, or 5 half-lives of investigational drug, whichever is longer
- Recent (within 1 year) history of, or current drug or alcohol abuse
- Have any other conditions, which, in the opinion of the Investigator or Sponsor would make the subject unsuitable for inclusion, or could interfere with the subject participating in or completing the Study
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: ARCT-810
Ascending single doses of ARCT-810 administered intravenously
|
ARCT-810 is an investigational medicinal product comprising OTC mRNA formulated in a lipid nanoparticle (LNP) under development.
|
Placebo Comparator: Placebo
Single doses of 0.9% Saline administered intravenously
|
The placebo for this study is 0.9% sterile saline.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Incidence, severity and dose-relationship of AEs
Time Frame: 4 weeks
|
Safety and tolerability of ARCT-810 assessed by determining the incidence, severity and dose-relationship of AEs by dose
|
4 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of participants with changes in plasma pharmacokinetic parameters after single dose of ARCT-810
Time Frame: Up to 15 days
|
The plasma pharmacokinetics (concentration-time results) of ARCT-810 will be assessed following single dose
|
Up to 15 days
|
Number of participants with changes in urine pharmacokinetic parameters after single dose of ARCT-810
Time Frame: Up to 24 hours
|
The urine pharmacokinetics (concentration-time results) of ARCT-810 will be assessed following single dose
|
Up to 24 hours
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Christian Schwabe, MD, Auckland Clinical Studies (ACS) Ltd.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Metabolic Diseases
- Brain Diseases
- Central Nervous System Diseases
- Nervous System Diseases
- Genetic Diseases, Inborn
- Genetic Diseases, X-Linked
- Metabolism, Inborn Errors
- Brain Diseases, Metabolic
- Brain Diseases, Metabolic, Inborn
- Amino Acid Metabolism, Inborn Errors
- Urea Cycle Disorders, Inborn
- Ornithine Carbamoyltransferase Deficiency Disease
Other Study ID Numbers
- ARCT- 810-01
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Ornithine Transcarbamylase Deficiency
-
Ultragenyx Pharmaceutical IncCompletedOrnithine Transcarbamylase (OTC) DeficiencyUnited Kingdom, United States, Canada, Spain
-
Ultragenyx Pharmaceutical IncActive, not recruitingOrnithine Transcarbamylase (OTC) DeficiencyCanada, United States, France, Spain, United Kingdom
-
Ultragenyx Pharmaceutical IncTerminatedOrnithine Transcarbamylase DeficiencyUnited States
-
Eunice Kennedy Shriver National Institute of Child...Children's National Research InstituteTerminatedPhase I Pilot Study of Liver-Directed Gene Therapy for Partial Ornithine Transcarbamylase DeficiencyOrnithine Transcarbamylase Deficiency Disease
-
iECURE, Inc.RecruitingUrea Cycle Disorders, Inborn | Ornithine Transcarbamylase Deficiency | Ornithine Transcarbamylase Deficiency Disease | Ornithine Carbamoyltransferase Deficiency (Disorder)United Kingdom
-
University of PennsylvaniaTerminatedOrnithine Transcarbamylase Deficiency Disease
-
Arcturus Therapeutics, Inc.RecruitingOTC Deficiency | Ornithine Transcarbamylase Deficiency | OTCDSpain, Belgium, United Kingdom, Sweden
-
University College, LondonRecruitingOrnithine Transcarbamylase DeficiencyUnited Kingdom
-
Arcturus Therapeutics, Inc.Active, not recruitingOrnithine Transcarbamylase DeficiencyUnited States
-
Ultragenyx Pharmaceutical IncCompletedOrnithine Transcarbamylase DeficiencyUnited States
Clinical Trials on ARCT-810
-
Arcturus Therapeutics, Inc.RecruitingOTC Deficiency | Ornithine Transcarbamylase Deficiency | OTCDSpain, Belgium, United Kingdom, Sweden
-
Arcturus Therapeutics, Inc.Active, not recruitingOrnithine Transcarbamylase DeficiencyUnited States
-
Arcturus Therapeutics, Inc.RecruitingCOVID-19 | Corona Virus Infection | SARS-CoV-2 InfectionUnited States, Singapore
-
Arcturus Therapeutics, Inc.Completed
-
Arcturus Therapeutics, Inc.Terminated
-
Arcturus Therapeutics, Inc.Novotech CRORecruiting
-
Supernus Pharmaceuticals, Inc.CompletedAttention Deficit Hyperactivity Disorder (ADHD)United States
-
Supernus Pharmaceuticals, Inc.CompletedAttention Deficit Hyperactivity Disorder (ADHD)United States
-
Supernus Pharmaceuticals, Inc.CompletedConduct Disorder | Attention Deficit Disorder With HyperactivityUnited States
-
Arcturus Therapeutics, Inc.TerminatedCovid19 | Corona Virus Infection | SARS-CoV InfectionUnited States, Singapore